These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36454565)

  • 1. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.
    Katz MHG; Herman JM; O'Reilly EM
    JAMA Oncol; 2023 Feb; 9(2):277-278. PubMed ID: 36454565
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
    Hintz B; Lee VJ
    JAMA Oncol; 2023 Feb; 9(2):277. PubMed ID: 36454584
    [No Abstract]   [Full Text] [Related]  

  • 3. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
    Grossberg AJ; Jethwa KR; Ellsworth SG
    JAMA Oncol; 2023 Feb; 9(2):275. PubMed ID: 36454560
    [No Abstract]   [Full Text] [Related]  

  • 4. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
    Dincer N; Ugurluer G; Ozyar E
    JAMA Oncol; 2023 Feb; 9(2):276-277. PubMed ID: 36454557
    [No Abstract]   [Full Text] [Related]  

  • 5. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.
    Hall WA; Evans DB; Tsai S
    JAMA Oncol; 2023 Feb; 9(2):275-276. PubMed ID: 36454556
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
    Katz MHG; Shi Q; Meyers J; Herman JM; Chuong M; Wolpin BM; Ahmad S; Marsh R; Schwartz L; Behr S; Frankel WL; Collisson E; Leenstra J; Williams TM; Vaccaro G; Venook A; Meyerhardt JA; O'Reilly EM
    JAMA Oncol; 2022 Sep; 8(9):1263-1270. PubMed ID: 35834226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neoadjuvant and adjuvant treatment of pancreatic cancer].
    Springfeld C; Hackert T; Jäger D; Büchler MW; Neoptolemos JP
    Chirurg; 2020 Aug; 91(8):636-641. PubMed ID: 32300820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
    Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
    Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
    Mavros MN; Moris D; Karanicolas PJ; Katz MHG; O'Reilly EM; Pawlik TM
    JAMA Surg; 2021 Jul; 156(7):663-672. PubMed ID: 33787841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
    Saif A; Verbus E; Erickson B; Kamgar M; Tsai S; Evans D; Hernandez JM; Hall WA
    Ann Surg Oncol; 2023 Feb; 30(2):688-690. PubMed ID: 36427115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis.
    Petrelli F; Ghidini M; Macchini M; Orsi G; Peretti U; Andrea S; Cascinu S; Reni M
    J Gastrointest Cancer; 2023 Dec; 54(4):1376-1379. PubMed ID: 36881248
    [No Abstract]   [Full Text] [Related]  

  • 13. Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501).
    Snyder RA; Dueck AC; Fruth B; Shi Q; Hubbard JM; Herman JM; O'Reilly EM; Katz MHG
    Ann Surg; 2023 Oct; 278(4):598-608. PubMed ID: 37334719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
    Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
    Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer.
    Chawla A
    J Surg Oncol; 2021 May; 123(6):1423-1431. PubMed ID: 33831254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
    Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
    Landry J; Catalano PJ; Staley C; Harris W; Hoffman J; Talamonti M; Xu N; Cooper H; Benson AB
    J Surg Oncol; 2010 Jun; 101(7):587-92. PubMed ID: 20461765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis.
    Yoo C; Lee SS; Song KB; Jeong JH; Hyung J; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Lee SS; Kim JH; Jin HS; Park JH; Hwang DW; Lee JH; Lee W; Chang HM; Kim KP; Ryoo BY; Kim SC
    Br J Cancer; 2020 Aug; 123(3):362-368. PubMed ID: 32433600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.